A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Biosplice Therapeutics, Inc
Start Date
May 4, 2022
End Date
April 30, 2027
Administered By
Duke Cancer Institute
Awarded By
Biosplice Therapeutics, Inc
Start Date
May 4, 2022
End Date
April 30, 2027